Correlation between highly sensitive troponin I and lipid profile in patient of myocardial infarction (MI) in case-control study.

Rajeev  Ranjan; Priti Abha; Dilip  Kumar; Rekha  Kumari; Kumar  Pranay

doi:10.51168/sjhrafrica.v6i12.2271

Authors

Rajeev Ranjan Senior Resident, Department of Biochemistry, AIIMS Deoghar, Jharkhand, India.
Priti Abha Senior Resident, Department of Biochemistry, AIIMS Deoghar, Jharkhand, India.
Dilip Kumar Senior Resident, Department of Biochemistry, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
Rekha Kumari Senior Resident, Department of Biochemistry, AIIMS Patna, Bihar, India.
Kumar Pranay Scientist I, Department of Biochemistry, Medical College Indira Gandhi Institute of Medical Sciences, Patna.

DOI:

https://doi.org/10.51168/sjhrafrica.v6i12.2271

Keywords:

Myocardial infarction, Lipid profile, High-sensitivity cardiac Troponin I (hs-cTnI)

Abstract

Background

Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Dyslipidemia is a major risk factor for coronary artery disease. High-sensitivity cardiac Troponin I (hs-cTnI) is a specific biomarker of myocardial injury.

Aim

To evaluate the correlation between high-sensitivity cardiac Troponin I and lipid profile parameters in patients with myocardial infarction.

Methods

This hospital-based case-control study was conducted at Indira Gandhi Institute of Medical Sciences, Patna, from October 2022 to March 2023. A total of 120 participants were enrolled, including 50 MI cases and 70 healthy controls. Serum lipid profile and hs-cTnI levels were measured using standardized laboratory methods. Statistical analysis was performed using an independent t-test and Pearson correlation analysis.

Results

Mean total cholesterol, triglycerides, LDL, and VLDL levels were significantly higher among cases compared to controls (p < 0.0001), while HDL levels were significantly lower (p < 0.0001). The mean hs-cTnI level among cases was 534.5 ± 224.1 pg/ml compared to 1.572 ± 1.445 pg/ml in controls (p < 0.0001). A strong positive correlation was observed between hs-cTnI and total cholesterol (R² = 0.8612), triglycerides (R² = 0.9155), and LDL (R² = 0.4109), while HDL showed a negative correlation (R² = 0.1706). Elevated hs-cTnI was observed in 46 out of 50 cases.

Conclusion

High-sensitivity cardiac Troponin I levels are significantly associated with deranged lipid parameters in MI patients. Routine lipid screening may help identify individuals at risk, especially in resource-limited settings.

References

Makam AN, Nguyen OK. Use of cardiac biomarker testing in the emergency department. JAMA internal medicine. 2015 Jan 1;175(1):67-75.

Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W,et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. Jama. 2017 Nov 21;318(19):1913-24.

De Silva LD, Kumar A, Sathian B. The significance of lipid profile and positive troponin in redicting cardiac event. Kathmandu Univ Med J (KUMJ). 2009 Jul-Sep;7(27):263-7. doi: 10.3126/kumj.v7i3.2735. PMID: 20071874.

Kumar A, Sathian B. The clinical utility of lipid profileand positive troponin in predicting future cardiac events. Asian Pac J Trop Dis. 2012;2:66-9.

Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J.2010;31(18):2197204.

Rubini Gimenez M, Hoeller R, Reichlin T. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. Int J Cardiol. 2013;168:3896–3901

Yan I, Börschel CS, Neumann JT, Sprünker NA, Makarova N, Kontto J, Kuulasmaa K et al. High-sensitivity cardiac troponin I levels and prediction of heart failure: results from the BiomarCaRE Consortium. Heart Failure. 2020 May 1;8(5):401-11.

Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. New England Journal of Medicine. 2009 Aug 27;361(9):868-77.

Boeddinghaus J, Twerenbold R, Nestelberger T, Koechlin L, Wussler D, Meier M et al. Clinical use of a new high-sensitivity cardiac troponin I assay in patients with suspected myocardial infarction. Clinical chemistry. 2019 Nov 1;65(11):1426-36.

Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah AS et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. Jama. 2011 Mar 23;305(12):1210-6.

Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54–61

Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature. 2003;424:35–41

Farah CS, Reinach FC. The troponin complex and regulation of muscle contraction. FASEB J. 1995;9:755–767.

Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. Jama. 2017 Nov 21;318(19):1913-24

Bularga A, Lee KK, Stewart S, Ferry AV, Chapman AR, Marshall L et al. High-Sensitivity Troponin and the Application of Risk Stratification Thresholds in Patients With Suspected Acute Coronary Syndrome. Circulation. 2019 Nov 5;140(19):1557-1568.

Wildi K, Nelles B, Twerenbold R, Rubini Giménez M, Reichlin T, Singeisen H, et al; Safety and efficacy of the 0 h/3 h protocol for rapid rule out of myocardial infarction. Am. Heart J.. 2016; 181:16–25.

Kozinski M, Krintus M, Kubica J, Sypniewska G. High-sensitivity cardiac troponin assays: from improved analytical performance to enhanced risk stratification. Crit Rev Clin Lab Sci. 2017 Apr 3;54(3):143-72.

Kumar A, Sathian B. The clinical utility of lipid profile and positive troponin in predicting future cardiac events. Asian Pacific Journal of Tropical Disease. 2012 Feb 1;2(1):66-9.